29th Jan 2014 14:15
LONDON (Alliance News) - Vectura Group PLC said Wednesday that its partner Sandoz has received marketing approval for its AirFluSal Forspiro asthma inhaler in Romania.
Vectura will receive a EUR1.5 million milestone payment as a result of the marketing authorisation. The product has already received approval in Germany, Sweden and Hungary.
Sandoz is the generics division of Swiss pharmaceutical company Novartis AG.
Shares in Vectura were trading up 1.9% at 158.96 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L